Cerebrospinal Fluid Biomarkers for Alzheimer’s Disease in the Era of Disease-Modifying Treatments

Correct in vivo diagnosis of Alzheimer’s disease (AD) helps to avoid administration of disease-modifying treatments in non-AD patients, and allows the possible use of such treatments in clinically atypical AD patients. Cerebrospinal fluid (CSF) biomarkers offer a tool for AD diagnosis. A reduction i...

Descripción completa

Detalles Bibliográficos
Autores principales: Paraskevas, George P., Kapaki, Elisabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Opinion
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534246/
https://www.ncbi.nlm.nih.gov/pubmed/34679323
http://dx.doi.org/10.3390/brainsci11101258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8534246/
https://www.ncbi.nlm.nih.gov/pubmed/34679323
http://dx.doi.org/10.3390/brainsci11101258

Ejemplares similares